A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
Condition studied
Neovascular age-related macular degeneration
Investigational medicinal product(s)
Every trial of Surabgene Lomparvovec and Ranibizumab across our registers →
Eligibility
Primary endpoint
Annualized intravitreal anti-VEGF injection rate through Week 54.
Endpoint detail
Change from Baseline in BCVA at Year 3., Annualized intravitreal anti-VEGF injection rate through Year 3., Incidence and severity of ocular AEs in the study eye and fellow eye, Change from Baseline in area of macular atrophy based on FAF at assessed time points in the study eye
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2024-512298-28-00 on CTIS ↗ ← All trials in the EU